Already with 24 locations across the U.K., Concept Life Sciences is underway with its next expansion, announcing recently that it is now offering its drug discovery and development services in the United States.
The CRO--formed in 2014 with the joining of Peakdale Molecular, Scientific Analysis Laboratories and Resource & Environmental Consultants--has selected Heidi Schulze to head the U.S. operation. In pharma and biotech, Concept says it offers services ranging in areas from early stage development to candidate selection and registration.
In addition to its biopharma suite, the company operates in industries including food, agrochemical and petrochemical.
Schulze will be based on the U.S. east coast managing sales while also assisting the western U.S. operation get on its feet. The company’s approach “has been of significant interest to customers within the U.K., but has also attracted the attention of customers in the U.S.,” chairman Michael Fort said in a statement. After a U.S. pilot program, the group decided it was time to launch in the country, Fort added.
Since its 2014 formation, Concept Life Sciences has expanded with the purchase of CXR Biosciences and Agenda1 Analytical Services in 2015. It plans a mix of “organic growth and targeted acquisition" to continue to bulk up.
And it’s not alone in looking to grow through acquisitions, with CROs around the globe moving to consolidate in recent months to keep their offerings competitive. In May, U.S. companies Accelovance and Veristat both bought European outfits--THERAMetrics and Spero Oncology, respectively--to expand on the continent.
Before those buys, Greenwich, CT’s Aptuit bought Exquiron in Switzerland and China’s WuXi snapped up Germany’s Crelux, all to make European inroads.
- here's the release
U.K. CRO emerges from $100M in deals with plans for more M&A